21
Feb
Healthy activity levels expected in 2024
2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels. In 2024, we expect similar levels of activity, in the $225 billion to $275 billion range across all subsectors. Executives will continue to deploy cash balances and seek out areas of innovation and clinical differentiation to help address remaining growth challenges in the latter half of the decade.
Despite some...